Publicacións en colaboración con investigadores/as de Hospital General Universitario de Elche (37)

2024

  1. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787

  2. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry

    Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145

  3. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686

  4. Physical Activity in Patients with Advanced Cancer: Sociodemographic, Clinical, and Psychological Correlates

    Brain Sciences, Vol. 14, Núm. 6

  5. Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial

    World Journal of Gastrointestinal Oncology, Vol. 16, Núm. 2, pp. 386-397

2023

  1. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089

  2. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

  3. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15

2022

  1. A Delphi Study on the Management of Neuropathic Cancer Pain in Spain: The DOLNEO Study

    Journal of Pain Research, Vol. 15, pp. 2181-2196

  2. Anxiety and depression in patients with advanced cancer during the COVID-19 pandemic

    Supportive Care in Cancer, Vol. 30, Núm. 4, pp. 3363-3370

  3. Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries

    Cancer Investigation, Vol. 40, Núm. 1, pp. 1-13

  4. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

  5. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

  6. Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry

    Biomedicines, Vol. 10, Núm. 1

  7. Resilience, Social Support, and Anxious Preoccupation in Patients with Advanced Cancer during COVID-19 Pandemic

    Cancer Investigation, Vol. 40, Núm. 6, pp. 475-482

  8. Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

    ESMO Open, Vol. 7, Núm. 3

2021

  1. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

    Therapeutic Advances in Medical Oncology, Vol. 13

  2. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

    Gastric Cancer, Vol. 24, Núm. 2, pp. 445-456

  3. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry

    Gastric Cancer, Vol. 24, Núm. 4, pp. 926-936

  4. Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)

    Health and Quality of Life Outcomes, Vol. 19, Núm. 1